| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Dicer, Drosha, and outcomes in patients with ovarian cancer.
|
N Engl J Med
|
2008
|
8.77
|
|
2
|
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
|
Clin Cancer Res
|
2009
|
3.07
|
|
3
|
Focus on bladder cancer.
|
Cancer Cell
|
2004
|
2.59
|
|
4
|
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
|
Mol Cancer Ther
|
2003
|
2.08
|
|
5
|
Rewired ERK-JNK signaling pathways in melanoma.
|
Cancer Cell
|
2007
|
2.03
|
|
6
|
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.
|
Am J Pathol
|
2002
|
1.96
|
|
7
|
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
|
J Clin Oncol
|
2004
|
1.84
|
|
8
|
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
|
Cancer Res
|
2008
|
1.65
|
|
9
|
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
|
Cancer Res
|
2007
|
1.62
|
|
10
|
Src activation by β-adrenoreceptors is a key switch for tumour metastasis.
|
Nat Commun
|
2013
|
1.62
|
|
11
|
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.
|
J Biol Chem
|
2010
|
1.58
|
|
12
|
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels.
|
Neoplasia
|
2010
|
1.51
|
|
13
|
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB.
|
Clin Cancer Res
|
2003
|
1.49
|
|
14
|
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis.
|
J Biol Chem
|
2005
|
1.38
|
|
15
|
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1.
|
Cancer Res
|
2004
|
1.33
|
|
16
|
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.
|
J Biol Chem
|
2009
|
1.32
|
|
17
|
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
|
Clin Cancer Res
|
2006
|
1.30
|
|
18
|
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
|
Clin Cancer Res
|
2008
|
1.30
|
|
19
|
Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma.
|
Cancer Res
|
2002
|
1.30
|
|
20
|
Role and regulation of the thrombin receptor (PAR-1) in human melanoma.
|
Oncogene
|
2003
|
1.30
|
|
21
|
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
|
Clin Cancer Res
|
2002
|
1.27
|
|
22
|
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.
|
J Biol Chem
|
2004
|
1.24
|
|
23
|
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8.
|
Clin Cancer Res
|
2003
|
1.23
|
|
24
|
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.
|
Semin Cancer Biol
|
2010
|
1.23
|
|
25
|
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.
|
Cancer Res
|
2004
|
1.22
|
|
26
|
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.
|
Cancer Res
|
2005
|
1.22
|
|
27
|
Cellular adhesion pathways and metastatic potential of human melanoma.
|
Cancer Biol Ther
|
2002
|
1.21
|
|
28
|
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma.
|
J Biol Chem
|
2003
|
1.19
|
|
29
|
Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma.
|
J Biol Chem
|
2009
|
1.18
|
|
30
|
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
|
Pigment Cell Res
|
2006
|
1.17
|
|
31
|
Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.
|
Am J Pathol
|
2008
|
1.17
|
|
32
|
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.
|
Cancer Res
|
2003
|
1.17
|
|
33
|
The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo.
|
Cancer Res
|
2005
|
1.16
|
|
34
|
Transcriptional regulation of metastasis-related genes in human melanoma.
|
Clin Exp Metastasis
|
2003
|
1.15
|
|
35
|
EphA2 overexpression promotes ovarian cancer growth.
|
Cancer Biol Ther
|
2008
|
1.13
|
|
36
|
The dicey role of Dicer: implications for RNAi therapy.
|
Cancer Res
|
2010
|
1.13
|
|
37
|
Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
|
Clin Cancer Res
|
2005
|
1.12
|
|
38
|
Therapeutic destruction of insulin receptor substrates for cancer treatment.
|
Cancer Res
|
2013
|
1.12
|
|
39
|
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.
|
J Clin Invest
|
2013
|
1.11
|
|
40
|
Inflammation and melanoma metastasis.
|
Pigment Cell Melanoma Res
|
2009
|
1.11
|
|
41
|
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
|
Cancer Res
|
2007
|
1.11
|
|
42
|
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
|
Cancer Res
|
2005
|
1.11
|
|
43
|
Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1.
|
J Biol Chem
|
2005
|
1.10
|
|
44
|
Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor.
|
Cancer Metastasis Rev
|
2007
|
1.08
|
|
45
|
Transcriptional control of the melanoma malignant phenotype.
|
Cancer Biol Ther
|
2008
|
1.08
|
|
46
|
Chitosan hydrogel for localized gene silencing.
|
Cancer Biol Ther
|
2011
|
1.07
|
|
47
|
A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.
|
Clin Cancer Res
|
2003
|
1.03
|
|
48
|
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
|
Mol Cancer Ther
|
2004
|
1.03
|
|
49
|
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
|
Cancer Res
|
2009
|
1.03
|
|
50
|
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans.
|
Cancer Res
|
2008
|
1.03
|
|
51
|
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
|
J Invest Dermatol
|
2006
|
1.02
|
|
52
|
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
|
Proc Natl Acad Sci U S A
|
2010
|
1.02
|
|
53
|
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
|
Neoplasia
|
2008
|
1.02
|
|
54
|
Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.
|
Cancer Res
|
2009
|
1.02
|
|
55
|
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
|
Am J Clin Dermatol
|
2008
|
1.02
|
|
56
|
Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
|
Clin Cancer Res
|
2006
|
1.00
|
|
57
|
Retracted
Targeting EGFR in bladder cancer.
|
World J Urol
|
2007
|
0.99
|
|
58
|
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.
|
J Urol
|
2007
|
0.99
|
|
59
|
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia.
|
Proc Natl Acad Sci U S A
|
2007
|
0.98
|
|
60
|
ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics.
|
Cancer
|
2006
|
0.98
|
|
61
|
Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression.
|
Cancer Res
|
2011
|
0.98
|
|
62
|
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
|
Cancer Res
|
2011
|
0.98
|
|
63
|
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.
|
Lab Invest
|
2008
|
0.96
|
|
64
|
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia.
|
Blood
|
2008
|
0.94
|
|
65
|
Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment.
|
Cancer Res
|
2004
|
0.94
|
|
66
|
ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis.
|
Cancer Res
|
2007
|
0.94
|
|
67
|
Driving transcriptional regulators in melanoma metastasis.
|
Cancer Metastasis Rev
|
2012
|
0.92
|
|
68
|
CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.
|
PLoS One
|
2010
|
0.92
|
|
69
|
Emerging roles of PAR-1 and PAFR in melanoma metastasis.
|
Cancer Microenviron
|
2008
|
0.92
|
|
70
|
Regulation of gene expression in melanoma: new approaches for treatment.
|
J Cell Biochem
|
2005
|
0.92
|
|
71
|
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
|
J Invest Dermatol
|
2004
|
0.91
|
|
72
|
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.
|
Eur J Cancer
|
2004
|
0.90
|
|
73
|
Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin.
|
Cancer Res
|
2012
|
0.90
|
|
74
|
Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: modulation of genomic stability and invasion.
|
J Cell Physiol
|
2005
|
0.89
|
|
75
|
Why is melanoma so metastatic?
|
Pigment Cell Melanoma Res
|
2013
|
0.89
|
|
76
|
ATP11B mediates platinum resistance in ovarian cancer.
|
J Clin Invest
|
2013
|
0.88
|
|
77
|
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.
|
Oncotarget
|
2011
|
0.87
|
|
78
|
The sweet and bitter sides of galectins in melanoma progression.
|
Pigment Cell Melanoma Res
|
2012
|
0.86
|
|
79
|
ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells.
|
J Biol Chem
|
2002
|
0.86
|
|
80
|
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells.
|
Am J Pathol
|
2012
|
0.85
|
|
81
|
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
|
J Urol
|
2010
|
0.85
|
|
82
|
The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.
|
Int J Cancer
|
2014
|
0.82
|
|
83
|
A phase II study of gefitinib in patients with metastatic melanoma.
|
Melanoma Res
|
2011
|
0.82
|
|
84
|
Monocyte subpopulations in angiogenesis.
|
Cancer Res
|
2014
|
0.81
|
|
85
|
Gene expression profiling of human cutaneous melanoma: are we there yet?
|
Cancer Biol Ther
|
2004
|
0.78
|
|
86
|
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
|
J Urol
|
2008
|
0.77
|
|
87
|
The HOG-GLI face of melanoma.
|
Pigment Cell Res
|
2007
|
0.77
|
|
88
|
Construction and expression of intracellular anti-ATF-1 single chain Fv fragment: a modality to inhibit melanoma tumor growth and metastasis.
|
Methods
|
2004
|
0.76
|
|
89
|
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC.
|
Cancer Biol Ther
|
2006
|
0.76
|
|
90
|
Back to the embryonic stage: Nodal as a biomarker for breast cancer progression.
|
Breast Cancer Res
|
2012
|
0.76
|
|
91
|
Estela Medrano, 1943-2010.
|
Pigment Cell Melanoma Res
|
2010
|
0.75
|
|
92
|
Searching for the Achilles' heel of melanoma cells: new treatment modalities.
|
Pigment Cell Melanoma Res
|
2007
|
0.75
|
|
93
|
Crossing the junction in the gap of melanoma brain metastasis.
|
Pigment Cell Melanoma Res
|
2013
|
0.75
|